Bicyclic triazole α4 integrin inhibitors

Details Bicyclic triazole α4 integrin inhibitors Bicyclic triazole α4 integrin inhibitors

2005-11-08

2009-11-17

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S383000, C546S117000, C548S264200

Reexamination Certificate

active

07618983

ABSTRACT:
The compounds of the present invention are novel bicyclic triazole amino acid-derivatives useful as α4 integrin receptor antagonists. The invention is further directed to methods for treating integrin mediated disorders including, but not limited to, inflammatory, autoimmune and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

REFERENCES:
patent: 6303625 (2001-10-01), Hoekstra et al.
patent: 0741133 (1996-04-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 00/43354 (2000-07-01), None
patent: WO 00/43354 (2000-07-01), None
patent: WO 00/51974 (2000-09-01), None
patent: WO 0144230 (2001-06-01), None
Wagner et al, “Identification and Characterization of the T Lymphocyte Adhesion Receptor for an Alternative Cell Attachment Domain (CS-1) in Plasma Fibronectin,” The Journal of Cell Biology, 1989, pp. 1321-1330, vol. 109, The Rockefeller University Press.
Bayless et al, “Osteopontin is a ligand for the α4β1 integrin,” Journal of Cell Science, 1998, pp. 1165-1174, The Company of Biologists Limited, Great Britain.
Chuluyan et al, “α4-Integrin-dependent emigration of monocytes,” Springer Semin Immunopathol, 1995, pp. 391-404, vol. 16, Canada.
Adams et al “Section IV. Immunology, Endocrinology and Metabolic Diseases,” Chapter 18, Inhibitors of Integrin Alpha 4 Beta 1(vla-4), Annual Reports in Medicinal Chemistry, 1999, pp. 179-188, vol. 34, Academic Press.
Simmons et al, “Vascular Cell Adhesion Molecule-1 Expressed by Bone Marrow Stromal Cells Mediates the Binding of Hematopoietic Progenitor Cells,” Blood, 1992, pp. 388-395, vol. 80, No. 2.
Shroff et al, “Novel Modified Tripeptide Inhibitors of α4β7Mediated Lymphoid Cell Adhesion to MAdCAM-1,” Bioorganic & Medicinal Chemistry Letters, 1998, pp. 1601-1606, No. 8, Elsevier Science Ltd.
Yoshikawa et al, “Costimulation of Fibronectin Receptor Promotes FcγR-Mediated Rescue of IL-3-Dependent Bone Marrow-Derived Cells from Apoptosis1,” J. Immunology, 1996, pp. 1832-1840, vol. 156, The American Association of Immunologists.
Laberge et al, “Role of VLA-4 and LFA-1 in Allergen-Induced Airway Hyperresponsiveness and Lung Inflammation in the Rat,” Am J. Respir. Crit. Care Med., 1995, pp. 822-829, vol. 151.
Lin et al, “Selective, Tight-Binding Inhibitors of Integrin α4β1 that Inhibit Allergic Airway Responses,” J. Med Chem., 1999, pp. 920-934, vol. 42, American Chemical Society.
Molossi et al, “Blockage of Very Late Antigen-4 lntegrin Binding to Fibronectin with Connecting Segment-1 Peptide Reduces Accelerated Coronary Arteriopathy in Rabbit Cardiac Allografts,” J. Clin Invest., 1995, pp. 2601-2610, vol. 95, The American Society for Clinical Investigation, Inc.
Kling et al, “Mononuclear Leukocytes Invade Rabbit Arterial Intima During Thickening Formation via CD18- and VLA-4-Dependent Mechanisms and Stimulate Smooth Muscle Migration,” Circ Res., 1995, p. 1121-1128, vol. 77, No. 6.
Lumsden et al, “Anti-VLA-4 antibody reduces intimal hyperplasis in the endarterectomized carotid artery in nonhuman primates,” J. Vaasc. Surg., 1997, p. 87-93, vol. 26.
Labinaz et al, “Infusion of an antialpha4integrin antibody is associated with less neoadventitial formation after balloon injury of porcine coronary arteries,” Can J Cardio, 2000, pp. 187-196, vol. 16, No. 2.
O'Brien et al, “Vascular Cell Adhesion Molecule-1 is Expressed in Human Coronary Atherosclerotic Plaques,” J. Clin Invest., 1993, pp. 945-951, vol. 92, The American Society for Clinical Investigation, Inc.
Nakashima et al, “Upregulation of VCAM-1 and ICAM-1 at Atherosclerosis-Prone Sites on the Endothelium in the ApoE-Deficient Mouse,” Artheriosclerois, Thrombosis, and Vascular Biology, 1998, pp. 842-851, vol. 18.
Iiyama et al, “Patterns of Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 Expression in Rabbit and Mouse Atherosclerotic Lesions and at Sites Predisposed to Lesion Formation,” Circulation Research, 1999, pp. 199-207, vol. 85.
Shih et al, “Blocking Very Late Antigen-4 Integrin Decreases Leukocyte Entry and Fatty Streak Formation in Mice Fed an Atherogenic Diet,” Circulation Research, 1999, pp. 345-351, vol. 84.
Huo et al, “Role of Vascular Cell Adhesion Molecule-1 and Fuibronectin Connecting Segment-1 in Monocyte Rolling and Adhesion on Early Atherosclerotic Lesions,” Circulation Research, 2000, pp. 153-159, vol. 87.
Hamann et al, “Role of α4-Integrins in Lymphocyte Homing to Mucosal Tissues In Vivo,” Journal of Immunology, 1994, pp. 3282-3293.
Hanninen et al, “Vascular Addressins are Induced on Islet Vessels during Insulitis in Nonobese Diabetic Mice and Are Involved in Lymphoid Cell Binding to Islet Endothelium,” The Journal of Clinical Investigation, Inc., 1993, pp. 2590-2515, vol. 92.
Fong et al, Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), Immunol. Res., 1997, pp. 299-311, vol. 16.
Yang et al, “Involvement of β7Integrin and Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) in the Development of Diabetes in Nonobese Diabetic Mice,” Diabetes, 1997, pp. 1542-1547, vol. 46.
Gould et al, “Salt selection for basic drugs,” International Journal of Pharmaceutics, 1986, pp. 201-217, vol. 33, Elsevier Science Publishers B.V. (Biomedical Division).
Hancock et al, “Characteristics and Significance of the Amorphous State in Pharmaceutical Systems,” Journal of Pharmaceutical Sciences, 1997, pp. 1-12, vol. 86, No. 1, publication of the American Pharmaceutical Association and the American Chemical Society.
Powrie et al, “Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation,” Therapeutic Immunology, 1995, pp. 115-123, vol. 2, Blackwell Science Ltd.
Tamraz et al, “Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin,” Spring Semin Immunopathol, 1995, pp. 437-441, vol. 16.
Protective Groups in Organic Chemistry, ed. J.F.W.McOmie, Plenum Press, 1973.
T.W.Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
Barbadillo et al, “Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-α4 antibody in adjuvant arthritis,” Springer Semin Immunopathol, 1995, pp. 427-436, vol. 16, Springer-Verlag.

Affiliated with

Also associated with

Rating

Bicyclic triazole α4 integrin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic triazole α4 integrin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic triazole α4 integrin inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4126005